title: Outcome analysis of cervical adenosquamous carcinoma compared with adenocarcinoma.
abstract: OBJECTIVE
  To compare survival between patients with cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC).
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  National Taiwan University Hospital, Taipei, Taiwan.
  
  
  METHODS
  All patients with cervical AC or ASC who received definitive treatment from January 1995 to December 2009.
  
  
  METHODS
  Medical and histopathological record review.
  
  
  METHODS
  Overall and recurrence-free survival.
  
  
  RESULTS
  A total of 170 women received a histological diagnosis of AC and 42 of ASC. The median follow-up was 56.7 months. There were no significant differences in age, International Federation of Gynecology and Obstetrics (FIGO) stage, gravidity or treatment modality between women with AC and ASC. Patients with ASC had a higher percentage of poorly differentiated tumors than those with AC (33.3 vs. 15.3%, respectively; p= 0.014). Five year overall and recurrence-free survival was 66.8 and 58.9%, respectively, for women with AC and 69.5 and 61.9%, respectively, for those with ASC (p= 0.795 and p= 0.892, respectively). Survival outcomes in patients with early or advanced stage disease did not differ between the histological groups. No differences in failure patterns were found between the two groups. The FIGO stage and treatment modality were factors which affected overall and recurrence-free survival.
  
  
  CONCLUSIONS
  We did not find evidence to suggest that ASC subtypes indicate worse outcome. Cervical ASC could be categorized as one subtype of AC. The FIGO stage and treatment modalities have greater influence on outcomes than histological subtype.
authors.affiliation: Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
authors.forename: Jenny Ling-Yu
authors.initials: JL
authors.lastname: Chen
authors.forename: Jason Chia-Hsien
authors.initials: JC
authors.lastname: Cheng
authors.forename: Sung-Hsin
authors.initials: SH
authors.lastname: Kuo
authors.forename: Chi-An
authors.initials: CA
authors.lastname: Chen
authors.forename: Ming-Chieh
authors.initials: MC
authors.lastname: Lin
authors.forename: Chao-Yuan
authors.initials: CY
authors.lastname: Huang
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D018196:Carcinoma, Adenosquamous / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D012042:Registries; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy